Connect
← Return to Hormone Therapy (ADT) when ArteraAI Test says it's not necessary
Discussion
Hormone Therapy (ADT) when ArteraAI Test says it's not necessary
Prostate Cancer | Last Active: May 19 8:50am | Replies (47)Comment receiving replies
Maybe I misremember what Arterra recommends. I thought it was whether a second drug abiraterone (Zytiga) would be of benefit if added to the primary ADT agent. About 25% are recommended to take it; whereas about 75% would not benefit from adding to the primary ADT drug.
Replies to "Maybe I misremember what Arterra recommends. I thought it was whether a second drug abiraterone (Zytiga)..."
@thmssllvn For Gleason 8 or above that is what it does. For Gleason 7 (3+4 and 4+3) it is if there is short-term ADT benefit based on unspecified biomarkers. For Gleason 6 and 3+4 there is a statement if active surveillance is appropriate.
@thmssllvn The AteraAI may recommend many things, but the context for me was whether ADT was necessary given all of my metrics. That's really all I know. As I'm learning, no answers on any of this are definite, so I maybe got my hopes up about skipping ADT. But if it gives me even an iota of benefit, it sounds like it's worth it.
Connect
@thmssllvn
If you are on ADT alone for more than a year, it increases your chance of becoming Castrate resistant. If you add a drug like abiraterone or a lutamide That can extend the amount of time It takes.
Is ADT keeping you undetectable?